DURHAM, N.C. , May 13, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, and Mike Andriole, Chief Business and
– BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 – – DSTAT COVID 19 Trial Advances to Cohort 3 at Higher Dose – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a
DURHAM, N.C. , April 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, May 6, 2021
DURHAM, N.C. , April 26, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the appointment of Vicki Vakiener to its Board of Directors, effective
DURHAM, N.C. , April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming poster presentations at the American Association for Cancer Research
DURHAM, N.C. , March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will participate in a pre-recorded
– Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, reported topline results today from the first cohort of
DURHAM, N.C. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, February 25,
DURHAM, N.C. , Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix , Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today the closing of its previously announced underwritten public offering of
